Actavis (ACT) PT Lifted to $340 at Argus
Argus reiterated a Buy rating and boosted its price target on Actavis (NYSE: ACT) to $340.00 (from $310.00), noting the company is gnerating strong growth, while also preparing for the Allergan acquisition.
The firm is boosting 2015 stand-alone adj-EPS from $16.55 to $16.80, indicating 20% growth. The stock looks attractive a current levels, the analyst said.
For an analyst ratings summary and ratings history on Actavis click here. For more ratings news on Actavis click here.
Shares of Actavis closed at $289.44 yesterday.